

1 **Supplemental Table S1.** Ascorbate and glutathione redox states in Col-0 and *dhar* mutants.

2 Data show 100 x (reduced form/total) and are means of three biological replicates. No significant  
3 differences were observed in *dhar* mutants compared to Col-0 at  $P < 0.05$ .

4

---

	Ascorbate	Glutathione
5 Col-0	87 ± 1.25	91 ± 1.23
6 <i>dhar1</i>	86 ± 0.61	88 ± 1.07
7 <i>dhar2</i>	88 ± 1.65	90 ± 0.51
8 <i>dhar3</i>	89 ± 4.34	86 ± 1.18
9 <i>dhar1 dhar2</i>	86 ± 1.36	90 ± 2.34
10 <i>dhar1 dhar3</i>	85 ± 3.11	90 ± 2.09
11 <i>dhar2 dhar3</i>	86 ± 1.51	91 ± 1.43
12 <i>dhar1 dhar2 dhar3</i>	83 ± 1.53	88 ± 0.31

13

14

15

16

17

18

19 **Supplemental Table S2.** Ascorbate and glutathione redox states in Col-0, *cat2* and *cat2 dhar* mutants

20 Data show 100 x (reduced form/total) and are means of three biological replicates. \*Indicates  
21 significant difference compared to Col-0 while +indicates significant difference of *cat2 dhar* mutants  
22 compared to *cat2* at  $P < 0.05$ .

23

24

---

	Ascorbate	Glutathione
25		
26 Col-0	89 ± 0.92	91 ± 2.67
27 <i>cat2</i>	85 ± 2.14	64 ± 0.82*
28 <i>cat2 dhar1</i>	84 ± 1.54*	59 ± 3.45*
29 <i>cat2 dhar2</i>	79 ± 1.21*	50 ± 2.21* <sup>+</sup>
30 <i>cat2 dhar3</i>	84 ± 2.05	61 ± 2.39*
31 <i>cat2 dhar1 dhar2</i>	82 ± 2.52	79 ± 2.02* <sup>+</sup>
32 <i>cat2 dhar1 dhar3</i>	82 ± 1.37*	58 ± 4.31*
33 <i>cat2 dhar2 dhar3</i>	84 ± 3.21	58 ± 2.93*
34 <i>cat2 dhar1 dhar2 dhar3</i>	80 ± 0.71*	86 ± 1.44 <sup>+</sup>

35

36

37

38 **Supplemental Table S3.** T2 segregation of DHAR-complemented lines growing in vitro on agar.

39 Transformed plants were identified *in vitro* based on their resistance (R) or sensitivity (S) to  
40 hygromycin.

41

---

42	Lines	Total	Hygromycin R	Hygromycin S	$\chi^2$ ( $P < 0.05$ )
43	<i>dhar1-1</i>	120	86	34	0.40
44	<i>dhar1-2</i>	116	88	28	0.83
45	<i>dhar2-1</i>	117	85	32	0.56
46	<i>dhar2-2</i>	120	85	35	0.29
47	<i>dhar3-1</i>	129	88	41	0.08
48	<i>dhar3-2</i>	114	92	22	0.16

49

50

51

52

53 **Supplemental Table S4.** T2 segregation of lesion phenotypes in complemented lines growing in soil.

54 Data show numbers of plants showing either the *cat2* lesion phenotype or the *cat2 dhar1 dhar2*

55 *dhar3* phenotype in two independent experiments performed on plants growing in soil.

---

56	Expt 1		Phenotype		
57	Lines	Total	<i>cat2</i>	quadruple mutant	$\chi^2$ ( $P < 0.05$ )
58	<i>dhar1-1</i>	44	33	11	1.00
59	<i>dhar1-2</i>	56	43	13	0.76
60	<i>dhar2-1</i>	47	36	11	0.80
61	<i>dhar2-2</i>	50	38	12	0.87
62	<i>dhar3-1</i>	46	35	11	0.86
63	<i>dhar3-2</i>	48	36	12	1.00

64

65	Expt 2		Phenotype		
66	Lines	Total	<i>cat2</i>	quadruple mutant	$\chi^2$ ( $P < 0.05$ )
67	<i>dhar1-1</i>	47	35	12	0.93
68	<i>dhar1-2</i>	52	41	11	0.52
69	<i>dhar2-1</i>	57	43	14	0.94
70	<i>dhar2-2</i>	39	29	10	0.93
71	<i>dhar3-1</i>	51	39	12	0.81
72	<i>dhar3-2</i>	45	33	12	0.80

73

74

75

76 **Supplemental Table S5.** Glutathione redox states in Col-0 and *dhar* mutants after treatment with 3-  
77 amino-1,2,4-triazole.

78 Data show 100 x (reduced form/total) and are means of three biological replicates. \*Indicates  
79 significant difference compared to Col-0 at  $P < 0.05$ .

---

80	Col-0	41 ± 3.61
81	<i>dhar1</i>	41 ± 5.00
82	<i>dhar2</i>	36 ± 6.28
83	<i>dhar3</i>	27 ± 6.40
84	<i>dhar1 dhar2</i>	66 ± 0.87*
85	<i>dhar1 dhar3</i>	54 ± 5.77
86	<i>dhar2 dhar3</i>	39 ± 2.97
87	<i>dhar1 dhar2 dhar3</i>	84 ± 2.75*

88

89

90

91

92

93 **Supplemental Table S6.** DNA primer sequences used in this study.

94	Oligonucleotide	Sequence	Technique
95			
96	For_CAT2	5'-CCCAGAGGTACCTCTTCTTCTCCCATG-3'	Genotyping
97	Rev_CAT2	5'-TCAGGGAACCTCATCCCATCGC-3'	Genotyping
98	For_DHAR1	5'-TTAGGTCCGTTCCAGCCAAC-3'	Genotyping
99	Rev_DHAR1	5'-AAGCTCTCAGGGACAGACCAG-3'	Genotyping
100	For_DHAR2	5'-AATGGGTGGCTGATTCTGAC-3'	Genotyping
101	Rev_DHAR2	5'-GATCCACATCACGCATTAC-3'	Genotyping
102	For_DHAR3	5'-GTTACTGACAATGGAGGAGAAG-3'	Genotyping
103	Rev_DHAR3	5'-GTGCCAAGGACAAATCTGC-3'	Genotyping
104	Lb1	5'-TGGACCGCTTGCTGCAACTCTC-3'	Genotyping
105	LB_Sail	5'-GAAATGGATAAATAGCCTTGCTTCC-3'	Genotyping
106	For_Actin2	5'-TTCCTCAGCACATTCCAGCAG-3'	RT-PCR
107	Rev_Actin2	5'-TTAACATTGCAAAGAGTTTCAAGG-3'	RT-PCR
108	For_CAT2	5'-GTGCTGACTTTCTCCGAGCT-3'	RT-PCR
109	Rev_CAT2	5'-CCTGAACCATCCATGTGCCT-3'	RT-PCR
110	For_DHAR1	5'-TGGCTCTGGAAATCTGTG-3'	RT-PCR
111	Rev_DHAR1	5'-AGCAAGGCATGTTCCAGATCC-3'	RT-PCR
112	For_DHAR2	5'-AATGGGTGGCTGATTCTGAC-3'	RT-PCR
113	Rev_DHAR2	5'-CCGCAACCACAATCTCTTTC-3'	RT-PCR
114	For_DHAR3	5'-GTTACTGACAATGGAGGAGAAG-3'	RT-PCR
115	Rev_DHAR3	5'-GTGCCAAGGACAAATCTGC-3'	RT-PCR
116	For_Actin2	5'-CTGTACGGTAACATTGTGCTCAG -3'	RT-qPCR
117	Rev_Actin2	5'-CCGATCCAGACACTGTACTTCC -3'	RT-qPCR
118	For_RCE1	5'-CTGTTACGGAAACCAATTC-3'	RT-qPCR
119	Rev_RCE1	5'-GGAAAAAGGTCTGACCGACA-3'	RT-qPCR
120	For_PR1	5'-AGGCTAACTACAACACTACGCTGCG-3'	RT-qPCR
121	Rev_PR1	5'-GCTTCTCGTTCACATAATCCAC-3'	RT-qPCR

122	For_PR2	5'-TCAAGGAGCTTAGCCTCACC-3'	RT-qPCR
123	Rev_PR2	5'-CGCCTAGCATCCCGTAGC-3'	RT-qPCR
124	For_ICS1	5'-TTGGTGGCGAGGAGAGTG-3'	RT-qPCR
125	Rev_ICS1	5'-CTTCCAGCTACTATCCCTGTCC-3'	RT-qPCR
126			
127	Amplification with stop codon		
128	For_Sall_DHAR1	5'-GCGCGTCGACAAATGGCTCTGGAAATCTGTGTG-3'	Cloning
129	Rev_DHAR1_stop_NotI	5'-TTTTGCGGCCGCTTCAAGGGTTAACCTTGGGAG-3'	Cloning
130	For_Sall_DHAR2	5'-ACGCGTCGACGTATGGCTCTAGATATCTGCGTGAAGG-3'	Cloning
131	Rev_DHAR2_stop_NotI	5'-ATTTGCGGCCGCTTTCACGCATTCACCTTCG-3'	Cloning
132	For_Sall_DHAR3	5'-ACGCGTCGACGTATGATAAGCCTTAGGTTTCAACCAAGC-3'	Cloning
133	Rev_DHAR3_stop_NotI	5'-ATTTGCGGCCGCTTTTAAACCATAACCTTTGGTCTCC-3'	Cloning
134			
135	Amplification without stop codon		
136	For_Sall_DHAR1	5'-GCGCGTCGACAAATGGCTCTGGAAATCTGTGTG-3'	Cloning
137	Rev_DHAR1_NotI	5'-TTTTGCGGCCGCTTAGGGTTAACCTTGGGAG-3'	Cloning
138	For_Sall_DHAR2	5'-ACGCGTCGACGTATGGCTCTAGATATCTGCGTGAAGG-3'	Cloning
139	Rev_DHAR2_NotI	5'-ATTTGCGGCCGCTTCGCATTCACCTTCGATTC-3'	Cloning
140	For_Sall_DHAR3	5'-ACGCGTCGACGTATGATAAGCCTTAGGTTTCAACCAAGC-3'	Cloning
141	Rev_DHAR3_NotI	5'-ATTTGCGGCCGCTTACCATAACCTTTGGTCTCC-3'	Cloning
142	For_pENTR2B	5'-CCAGGCATCAAACCTAAGCAG-3'	Cloning
143	Rev_pENTR2B	5'-CTTGTGCAATGTAACATCAGAG-3'	Cloning
144			

---